Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol. 2018;10(5):108–114. doi:10.4251/wjgo.v10.i5.10829770170
   PubMed Web of Science ®Google Scholar
• Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31(28):3501–3508. doi:10.1200/JCO.2012.44.564323980077
   PubMed Web of Science ®Google Scholar
• Petrelli F, Coinu A, Borgonovo K, et al. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol). 2014;26(8):488–496. doi:10.1016/j.clon.2014.04.03124856442
   PubMed Web of Science ®Google Scholar
• Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291–1295. doi:10.1158/1078-0432.CCR-07-223818316546
   PubMed Web of Science ®Google Scholar
• Brozovic A. The relationship between platinum drug resistance and epithelial-mesenchymal transition. Arch Toxicol. 2017;91(2):605–619. doi:10.1007/s00204-016-1912-728032148
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741–4751. doi:10.1038/onc.2010.21520531305
   PubMed Web of Science ®Google Scholar
• Wang R, Li Y, Hou Y, et al. The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget. 2015;6(9):7000–7010. doi:10.18632/oncotarget.319325760076
   PubMedGoogle Scholar
• Sleeman JP, Thiery JP. SnapShot: the epithelial-mesenchymal transition. Cell. 2011;145(1):162 e161. doi:10.1016/j.cell.2011.03.02921458675
   PubMed Web of Science ®Google Scholar
• Aasen T. Connexins: junctional and non-junctional modulators of proliferation. Cell Tissue Res. 2015;360(3):685–699. doi:10.1007/s00441-014-2078-325547217
   PubMed Web of Science ®Google Scholar
• Graham SV, Jiang JX, Mesnil M. Connexins and pannexins: important players in tumorigenesis, metastasis and potential therapeutics. Int J Mol Sci. 2018;19(6). doi:10.3390/ijms19061645
   Web of Science ®Google Scholar
• Maes M, Decrock E, Cogliati B, et al. Connexin and pannexin (hemi)channels in the liver. Front Physiol. 2014;4:405. doi:10.3389/fphys.2013.0040524454290
   PubMed Web of Science ®Google Scholar
• King TJ, Lampe PD. The gap junction protein connexin32 is a mouse lung tumor suppressor. Cancer Res. 2004;64(20):7191–7196. doi:10.1158/0008-5472.CAN-04-062415492231
   PubMed Web of Science ®Google Scholar
• Fujimoto E, Sato H, Shirai S, et al. Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line. Oncogene. 2005;24(22):3684–3690. doi:10.1038/sj.onc.120843015782139
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Ono T, Yamanoi A, El-Assal ON, Kohno H, Nagasue N. Expression of gap junction protein connexin32 in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Gastroenterol. 2004;39(8):763–768. doi:10.1007/s00535-003-1386-215338370
   PubMed Web of Science ®Google Scholar
• Edwards GO, Jondhale S, Chen T, Chipman JK. A quantitative inverse relationship between connexin32 expression and cell proliferation in a rat hepatoma cell line. Toxicology. 2008;253(1–3):46–52. doi:10.1016/j.tox.2008.08.01018809458
   PubMed Web of Science ®Google Scholar
• Zhao B, Zhao W, Wang Y, et al. Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways. Oncotarget. 2015;6(12):10116–10133. doi:10.18632/oncotarget.268725426556
   PubMedGoogle Scholar
• Yang Y, Zhang N, Zhu J, et al. Downregulated connexin32 promotes EMT through the Wnt/beta-catenin pathway by targeting Snail expression in hepatocellular carcinoma. Int J Oncol. 2017;50(6):1977–1988. doi:10.3892/ijo.2017.398528498415
   PubMed Web of Science ®Google Scholar
• Wang Q, You T, Yuan D, et al. Cisplatin and oxaliplatin inhibit gap junctional communication by direct action and by reduction of connexin expression, thereby counteracting cytotoxic efficacy. J Pharmacol Exp Ther. 2010;333(3):903–911. doi:10.1124/jpet.109.16527420215407
   PubMed Web of Science ®Google Scholar
• Sato A, Sekine M, Kobayashi M, Virgona N, Ota M, Yano T. Induction of the connexin 32 gene by epigallocatechin-3-gallate potentiates vinblastine-induced cytotoxicity in human renal carcinoma cells. Chemotherapy. 2013;59(3):192–199. doi:10.1159/00035471524335094
   PubMed Web of Science ®Google Scholar
• Yang AD, Fan F, Camp ER, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006;12(14 Pt 1):4147–4153. doi:10.1158/1078-0432.CCR-06-003816857785
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhu J, Zhang N, et al. Impaired gap junctions in human hepatocellular carcinoma limit intrinsic oxaliplatin chemosensitivity: a key role of connexin 26. Int J Oncol. 2016;48(2):703–713. doi:10.3892/ijo.2015.326626648344
   PubMed Web of Science ®Google Scholar
• Cauchy F, Soubrane O, Belghiti J. Liver resection for HCC: patient‘s selection and controversial scenarios. Best Pract Res Clin Gastroenterol. 2014;28(5):881–896. doi:10.1016/j.bpg.2014.08.01325260315
   PubMed Web of Science ®Google Scholar
• Virag P, Fischer-Fodor E, Perde-Schrepler M, et al. Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins. BMC Genomics. 2013;14:480. doi:10.1186/1471-2164-14-18123865481
   PubMed Web of Science ®Google Scholar
• Li QQ, Xu JD, Wang WJ, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009;15(8):2657–2665. doi:10.1158/1078-0432.CCR-08-237219336515
   PubMed Web of Science ®Google Scholar
• Yu M, Zhang C, Li L, Dong S, Zhang N, Tong X. Cx43 reverses the resistance of A549 lung adenocarcinoma cells to cisplatin by inhibiting EMT. Oncol Rep. 2014;31(6):2751–2758. doi:10.3892/or.2014.316324789679
   PubMed Web of Science ®Google Scholar
• Ren J, Chen Y, Song H, Chen L, Wang R. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem. 2013;114(6):1395–1403. doi:10.1002/jcb.2448123255418
   PubMed Web of Science ®Google Scholar
• Yu M, Han G, Qi B, Wu X. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma. Oncol Rep. 2017;37(4):2121–2128. doi:10.3892/or.2017.546228260043
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou F, Li Y, et al. Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition. Cell Cycle. 2017;16(24):2355–2365. doi:10.1080/15384101.2017.138897229108461
   PubMed Web of Science ®Google Scholar
• Cao L, Wan Q, Li F, Tang CE. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 2018;51(9):456–461.30037365
   PubMed Web of Science ®Google Scholar
• Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006;66(2):944–950. doi:10.1158/0008-5472.CAN-05-198816424029
   PubMed Web of Science ®Google Scholar
• Chang TH, Tsai MF, Su KY, et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011;183(8):1071–1079. doi:10.1164/rccm.201009-1440OC21037017
   PubMed Web of Science ®Google Scholar
• van Staalduinen J, Baker D, Ten Dijke P, van Dam H. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene. 2018. doi:10.1038/s41388-018-0378-x
   PubMedGoogle Scholar
• Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21(7):965. doi:10.3390/molecules21070965
   PubMed Web of Science ®Google Scholar
• McLachlan E, Shao Q, Wang HL, Langlois S, Laird DW. Connexins act as tumor suppressors in three-dimensional mammary cell organoids by regulating differentiation and angiogenesis. Cancer Res. 2006;66(20):9886–9894. doi:10.1158/0008-5472.CAN-05-430217047050
   PubMed Web of Science ®Google Scholar
• Xu HT, Li QC, Zhang YX, et al. Connexin 43 recruits E-cadherin expression and inhibits the malignant behaviour of lung cancer cells. Folia Histochem Cytobiol. 2008;46(3):315–321. doi:10.2478/v10042-008-0057-919056535
   PubMed Web of Science ®Google Scholar
• Yu SC, Xiao HL, Jiang XF, et al. Connexin 43 reverses malignant phenotypes of glioma stem cells by modulating E-cadherin. Stem Cells. 2012;30(2):108–120. doi:10.1002/stem.168522131169
   PubMed Web of Science ®Google Scholar
• Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007;13(23):7003–7011. doi:10.1158/1078-0432.CCR-07-126318056176
   PubMed Web of Science ®Google Scholar
• Wang SQ, Zhang SW, Zhang CZ, Zhao ZY, Wang YJ. Connexin 43 enhances oxaliplatin cytotoxicity in colorectal cancer cell lines. Cell Mol Biol (Noisy-le-grand). 2017;63(4):53–58. doi:10.14715/cmb/2017.63.4.9
   PubMed Web of Science ®Google Scholar
• Arora S, Heyza JR, Chalfin EC, Ruch RJ, Patrick SM. Gap junction intercellular communication positively regulates cisplatin toxicity by inducing DNA damage through bystander signaling. Cancers (Basel). 2018;10(10):368. doi:10.3390/cancers10100368
   PubMed Web of Science ®Google Scholar
• Quist AP, Rhee SK, Lin H, Lal R. Physiological role of gap-junctional hemichannels. Extracellular calcium-depen-dent isosmotic volume regulation. J Cell Biol. 2000;148(5):1063–1074.10704454
   PubMed Web of Science ®Google Scholar
• Zhou JZ, Jiang JX. Gap junction and hemichannel-independent actions of connexins on cell and tissue functions–an update. FEBS Lett. 2014;588(8):1186–1192. doi:10.1016/j.febslet.2014.01.00124434539
   PubMed Web of Science ®Google Scholar
• Yu M, Zou Q, Wu X, Han G, Tong X. Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway. Biomed Pharmacother. 2017;95:1844–1852. doi:10.1016/j.biopha.2017.09.06528968929
   PubMed Web of Science ®Google Scholar